Global B2B Pharmaceutical Sourcing · Dossier Licensing · Named-Patient Access
💬 WhatsApp · Sign in · Register
Aflibercept-mrbb bulk supplier for pharma manufacturers

Aflibercept-Mrbb Suppliers & Bulk Manufacturers

Available Forms: Intravitreal injection (liquid solution)

Available Strengths: 2mg (0.05 mL of a 40 mg/mL solution)

Reference Brands: Eylea(US & EU); Ahzantive - biosimilar to biosimilar to Eylea

Category: Biosimilars

Ahzantive, a biosimilar of Eylea, inhibits vascular endothelial growth factor (VEGF), reducing abnormal blood vessel growth in the eye. It effectively treats age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Benefits include similar efficacy, potentially lower costs, and improved access to crucial eye disease therapies.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

📘 Sourcing Guide

Product Description:

Ahzantive, a biosimilar of Eylea, is regulated in the EU and US, supported by dossiers demonstrating biosimilarity, safety, efficacy, and manufacturing quality in compliance with GMP and MDR standards. In the US, FDA approval involves extensive clinical validation, safety assessments, and comparability data. In the EU, CE marking certifies conformity with MDR standards for biosimilars. These products undergo validation, stability testing, and audits, with detailed documentation including safety profiles, clinical results, and manufacturing practices. For licensing procedures, approved dossiers, and latest regulatory updates, visit Pharmatradz. Ensuring compliance guarantees access to affordable, effective ophthalmic biosimilars supporting eye disease management worldwide.

Aflibercept-Mrbb — third party manufacturing & bulk supply

Aflibercept-Mrbb is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.
Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.
Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

What to include when you enquire

  • Destination market — determines which manufacturers hold the right site-level approvals
  • First order quantity and estimated annual volume
  • Whether you need a registration dossier or the product is already registered
  • Packaging, labelling and language requirements
  • Incoterms and required shelf life

Manufacturers of Aflibercept-Mrbb listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.

Request a quote for Aflibercept-Mrbb →
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing

Frequently Asked Questions

Aflibercept‑mrbb is used to treat eye conditions caused by abnormal blood vessel growth and fluid leakage in the retina, including wet age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). It works by inhibiting vascular endothelial growth factor (VEGF) to slow vision loss and improve retinal health.

The active ingredient is aflibercept, a recombinant fusion protein that binds VEGF-A, VEGF-B, and placental growth factor (PlGF). It is formulated as a sterile solution for intravitreal injection.

The trade name is Aflibercept‑mrbb.

Aflibercept‑mrbb is manufactured by licensed biopharmaceutical companies producing approved biosimilars according to regulatory standards.

The generic name is Aflibercept.

The brand name is Aflibercept‑mrbb.

It is manufactured in GMP-certified biopharmaceutical facilities, ensuring sterility, quality, and compliance for intravitreal use.

Related Products

Insulin‑Aspart‑Szjj

Strength:
100 units/mL

Form: SQ Injection

Reference Brands: NovoLog; Merilog is biosimilar to NovoLog.

View Details
Eculizumab‑Aeeb

Strength:
300 mg/20 mL (IV infusion),

Form: Injection for intravenous infusion

Reference Brands: Soliris, Bkemv- Biosimilar of Soliris, Epysqli- Biosimilar of Soliris

View Details
Omalizumab‑Igec

Strength:
75 mg/0.5 mL and 150 mg/mL

Form: Pre filled syringe

Reference Brands: Xolair, Omlyclo - a Biosimilar to Xolair

View Details
Tocilizumab-Bavi

Strength:
80 mg/4ml

Form: Intravenous infusion

Reference Brands: Actemra; Tofidence - biosimilar to Actemra (tocilizumab).

View Details
Enquire Now

Quick Response Guaranteed | Verified Suppliers

Subscribe to Our Newsletter

Stay updated on pharma trends and sourcing opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.